MedTrace Logo

Standard of Care Lifestyle Support for Stage III NSCLC Patients

NCT05287971 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-09-06

No results posted yet for this study

Summary

Offering an early-initiated supportive care program to stage III NSCLC patients to prevent deterioration of performance status and increase compliance of patients that complete chemoradiation as well as the patients receiving 12 months of durvalumab.

Conditions

  • Non Small Cell Lung Cancer

Interventions

BEHAVIORAL

Lifestyle advice

Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs.

Sponsors & Collaborators

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Dirk De Ruysscher, MD, PhD · Maastro

  • Karen Zegers, MD, PhD · Maastro

  • Lizza Hendriks, MD, PhD · Maastricht University Hospital (MUMC+)

  • Cheryl Roumen, PhD · Maastro

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-05-01
Completion
2025-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05287971 on ClinicalTrials.gov